Skip to content
English
  • There are no suggestions because the search field is empty.

Patient Populations That Benefit Most

The SphygmoCor XCEL is beneficial for a range of patient populations, with a primary focus on adults who have cardiovascular risk factors, including but not limited to:

  • Hypertension
  • Diabetes
  • Chronic kidney disease
  • Heart failure
  • Chronic obstructive pulmonary disease (COPD)

It is also valuable for individuals seeking to monitor arterial stiffness (particularly in older populations) and for researchers and clinicians assessing the effects of interventions or treatments on the vascular system.